{"id":"begrivac","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Begrivac is an individualized neoantigen-based therapeutic vaccine that is engineered based on each patient's unique tumor mutations. It works by training the patient's immune system to identify and eliminate cancer cells that express these personalized neoantigens, thereby enhancing anti-tumor immunity and potentially preventing recurrence.","oneSentence":"Begrivac is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:59.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (adjuvant setting, in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT01032395","phase":"PHASE3","title":"Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-03","conditions":"H1N1 Influenza Virus, Chronic Pulmonary Disease, Chronic Heart Disease","enrollment":342},{"nctId":"NCT01032408","phase":"PHASE3","title":"Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-04","conditions":"H1N1 Influenza Virus, Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":154},{"nctId":"NCT01147081","phase":"PHASE3","title":"Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-06","conditions":"Seasonal Influenza","enrollment":142}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Begrivac®","genericName":"Begrivac®","companyName":"Chiltern Pesquisa Clinica Ltda","companyId":"chiltern-pesquisa-clinica-ltda","modality":"Biologic","firstApprovalDate":"","aiSummary":"Begrivac is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for Melanoma (adjuvant setting, in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}